Recent advances in science and technology such as molecular diagnostic testing and the Human Genome project have bridged the barrier between genomics and healthcare industry. ‘Pharmacogenomics’ aims to combine the science of drugs and genomics for providing tailor-made medicines to patients based on their genetic background. This can lead to extremely precise, targeted therapies and reduction of side-effects. If implemented correctly, pharmacogenomics could potentially transform and drastically improve the current ‘patient care’ system. An innovation that allows the entire population of consumers to access a product or service that was initially only accessible to elite consumers is termed as ‘disruptive innovation’. The present paper discusses the provision of personalized medicine based on genetic testing as a ‘disruptive innovation’. The paper further reviews the prospect of using high-throughput genome sequencing technology ‘Next- Generation sequencing’ in pharmacogenomic science as a potential disruptive innovation. The paper also delves into the challenges faced in implementing this new medical technology into the health-care market. The information regarding the public perception and knowledge regarding pharmacogenomics and genetic testing is collected based on an online-based questionnaire. Our findings aim to provide an insightful blueprint about the current situation of pharmacogenomics in the healthcare market and provide probable solutions.